compani
elanco spin-off ipo expect outlook driven
conclus anticip click preview rais
sales/ep rang second quarter row time
vs project midpoint lli revis sale
midpoint yoy our/street ep
midpoint our/street sales/ep
beat est street
total sale quarter yoy volum price
fx our/street estim driven sale beat
human health therapi segment demonstr solid volum driven
top-lin growth diversifi new product cycl launch note
beat due one-tim adcirca tadalafil pah benefit
expect click divest
ipo process potenti yield total valu
boost capac must-win oncolog area lli outlook
assum us price increas remaind year remain
focus volume-driven growth expect us major biopharma make
similar announc price like hold merck buy
novarti nv rate transpar blueprint reveal sweep
chang translat lower price pharmaci counter consum
click us major biopharma preview note complet
share repurchas prm receiv board approv new
repo program diabet see limit downsid trulic long
rewind cv outcom trial show harm data expect soon addit
robust jardianc volum trend expect help azn declar
data/tradjenta carolina data support long-term growth remain
track launch new product next month kick
fda action galc migrain prophylaxi lasmiditan acut migrain
tanezumab oa pain despit safeti concern
remain one favorit name growth reiter
ep risk includ price pressur esp diabet commerci
rais sales/ep rang
rais non-gaap ep rang
revis midpoint our/street lli
compani
revenu target rais new midpoint
our/street revis sales/ep outlook impli yoy growth
midpoint think earli inning margin expans stori rais gross
margin target vs our/street maintain expens
midpoint in-lin our/street sg rang
midpoint below/abov our/street maintain tax rate vs our/
street higher revenu slightli better gross margin drove increas
lli non-gaap ep rang midpoint
spin-off elanco ipo expect
expect conclud strateg review enabl divestitur unit
ipo expect elanco ipo process play debt offer
equiti offer time plan divest initi ownership
tax-effici transact given lli goal preserv ownership elanco
ipo current valuat anim health space market-lead zoeti rate trade
ep ebitda think initi offer could higher
previous note state previous click divestitur make strateg sens
 believ could get spin-off assum ebitda valuat
full busi modest discount compani proce like go toward
and/or share repo conting alloc debt elanco newco think lli balanc
sheet could experi improv ad dri powder plan continu
report consolid financi elanco base busi full divestitur complet
consist us account rule enter quiet period regard elanco
transact expect color structur use potenti proce limit
deal price
sale beat came across human health exhibit
total sale quarter yoy volum price fx
our/street est driven sale beat across major therapeut categori
diabet oncolog neurosci immunolog cardiovascular diabet trulic
main growth driver beat our/street estim us ex-
us trulic volum uptak remain robust adj yoy strong market
growth class growth us continu share gain competit rise
novo nordisk nvo rate long-act ozemp semaglutid approv dec
ozemp share remain low-singl digit nvo navig access/reimburs issu
jardianc allianc revenu yoy estim street
jardianc us market share volum climb bode well
growth howev overal class growth yoy fallen mid-singl digit june
june safeti concern jnj invokana hang class lli short
intermediate-act insulin humalog humulin came vs our/street
sale respect long-act basaglar insulin glargin came missing/b
oncolog alimta sale yoy our/street
cyramza sale yoy our/street lartruvo
sale report yoy qoq below/abov our/street estim
verzenio abemaciclib came qoq third quarter us market
vs our/street estim verzenio nbrx share market three quarter
launch nv kisqali bode well sale ramp although kisqali first-in-class
inhibitor approv pre/peri-menopaus advanc breast cancer juli click
note immunolog taltz sale above/below our/street
estim match strong perform nv cosentyx johnson johnson
rate tremfya click note olumi sale qoq
mostli in-lin with/abov our/street estim robust uptak europ particularli
germani olumi lli lead volum growth driver europ cardiovascular adcirca
sale materi our/street estim assum
one-tim stock us us sale vs
combin human strong beat across therapeut categori lli anim
page
compani
ah busi slight miss vs our/street estim exhibit
breakdown product result vs our/street estim
sales/ep beat higher sales/low cost
total sale yoy
street ep yoy estim
 street rel estim higher sale partial off-set
higher cog sg /r expens incom tax gross margin came
our/street expens came
our/street sg our/street
lli tax rate came vs our/street yield ep
 street estim
catalyst-rich new product cycl unfold
catalyst includ updat strateg financi review elanco anim
busi call review lli alzheim diseas pipelin alzheim
associ intern confer aaic chicago il juli addit catalyst
includ taltz sbla file ankylos spondyl read-out trulic
rewind cv outcom studi full data expect ada meet jun interim
result jardianc heart failur pivot trial emperor-reduc -preserv late
fda action emgal galcanezumab pain franchis collect long-term
safeti data gladiat lasmiditan conduct drug-drug interact drive studi ahead
nda file addit hold announc posit top-lin result
tanezumab osteoarthr oa juli addit top-lin full data oa/
chronic back pain trial expect throughout
page
compani
interest net
page
compani
one-off guidanc updat sigilon deal
page
compani
valuat risk
pt assum trade ep reflect premium
current forward group averag forward price-to-earnings multipl think premium
group averag multipl justifi given lli diversifi volume-driven sale growth mid-singl digit
sale compound-annual-growth-rate oper leverag oper margin goe
price target support discount cash flow dcf intrins valu per share
risk thesi revolv around price commerci execut regulatori clinic risk
face upcom patent expir ciali alimta well recent
expir patent strattera competit pressur trulic semaglutid humalog
biosimilar insulin lispro expect off-set four launch verzenio emgal
olumi lasmiditan
compani mention note
compani buy john bori
johnson johnson rate
novarti ag nv rate
novo nordisk a/ nvo rate
zoeti inc rate
astrazeneca plc azn rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
